Posted inNews and Updates
Zabopegdutide Shows 81.8% MASH Fibrosis Response in Trial
Zabopegdutide shows 81.8% fibrosis response in Phase 2 MASH trials. Discover how this potential breakthrough treatment impacts liver health and prognosis.
Posted inNews and Updates
uniQure Targets BLA for AMT-130 Gene Therapy in Huntington’s
uniQure announces BLA submission plans for AMT-130, a breakthrough gene therapy targeting the root cause of Huntington’s disease. Learn the latest updates.
Posted inNews and Updates
Olorofim Shows Success in Phase 3 Invasive Aspergillosis Trial
Olorofim hits Phase 3 non-inferiority goals for treating Invasive Aspergillosis, offering a new hope for patients with drug-resistant fungal infections.
Posted inNews and Updates
FDA Reviews New Combo Therapy for Refractory B-Cell Lymphoma
The FDA is reviewing a new Lunsumio and Polivy combo for relapsed B-cell lymphoma. Discover how this dual-targeted therapy could transform patient outcomes.
Posted inNews and Updates
FDA Approves Utebzi: First Oral Carbapenem for UTIs
The FDA has approved Utebzi, the first oral carbapenem for complicated UTIs. Learn how this breakthrough antibiotic is transforming outpatient clinical care.
Posted inNews and Updates
New Human Trial Targets Aging Immune Cells to Boost Immunity
A landmark clinical trial is testing senolytic drugs to clear aging "zombie cells." Discover how this could revitalize the immune system and fight aging.
Posted inNews and Updates
Postbiotic Gummies May Reduce Gum Bleeding in Six Weeks
New clinical findings reveal that daily postbiotic gummies can reduce gum bleeding in just six weeks, offering a promising new tool for oral health care.
Posted inNews and Updates
Biogen Strengthens Immunology Portfolio with RayThera Buyout
Biogen confirms the acquisition of RayThera to expand its immunology pipeline. Discover how this strategic move strengthens its position in autoimmune therapy.
Posted inNews and Updates
New Implantable BCI Trial Offers Hope for Advanced ALS
A new clinical trial is testing a fully implantable BCI for advanced ALS patients, aiming to restore communication through direct neural signal decoding.
Posted inNews and Updates
FDA Extends Feedback Period for AI Medical Device Pilot
The FDA has extended the public feedback period for its AI medical device pilot program, aiming to refine regulations for machine learning in healthcare.